secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2026-06-03T12:08:44+00:00
Accession:  0001104659-26-069810
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Phase 1a TTX-MC138 trial meets safety endpoint; 64% stable disease at 6 months
--------------------------------------------------------------------------------

- 16 patients received 86 doses; median treatment 11.3 weeks (range 4-52.4 weeks).
- No dose-limiting toxicities; recommended Phase 2a dose set at 4.8 mg/kg.
- 9 of 14 evaluable patients (64%) achieved stable disease lasting ≥6 months.
- Three patients remain on study (at 21, 16, and 14 cycles); one thyroid cancer patient had dramatic thyroglobulin drop.
- Phase 2a trial initiated in ctDNA-positive colorectal cancer after curative-intent therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926069810/0001104659-26-069810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926069810/tm2616719d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-069810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer